NEWS WRAP: Hutchmed sells non-core asset to focus on cancer treatment
The drug maker is selling most of its stake in a joint venture with Shanghai Pharmaceuticals for $608 million By Teri Yu Hutchmed (China) Ltd. (HCM.US; 0013.HK; HCM.L), the biopharmaceutical…
